[250 Pages Report] The global demand for late stage chronic kidney disease therapeutics was valued at around US$ 4.7 Billion in 2019. However, with rising prevalence of chronic kidney disease across the globe, the overall late stage kidney disease therapeutics market is anticipated to surpass US$ 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period (2022 –2032)
| Report Attribute | Details |
|---|---|
| Late Stage Chronic Kidney Disease Therapeutics Market Projected Growth Rate (2022 to 2032) | 11.6% CAGR |
Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide due to its high morbidity and mortality rates. This fatal disease is usually caused by diabetes mellitus, hypertension, obesity, and aging.
Late stage chronic disease is an advanced stage of chronic renal disease where kidneys no longer function or work. This reduces the chances of survival and therefore requires proper treatment approaches including kidney transplant, dialysis and therapeutics. Among these, kidney transplant and dialysis are the only two effective treatments for CKD. However, dialysis is often costly and transplantation is limited by organ shortage. This has brought late stage chronic kidney disease therapeutics market into the spotlight.
Majority of the people with lower socioeconomic status and limited access to treatments are highly dependent on late stage chronic kidney disease therapeutics. These therapeutics can also be used in combination with dialysis.
Late stage chronic kidney disease therapeutics are drugs used for the treatment of late-stage chronic kidney disease induced hyperkalemia, hyperphosphatemia, hyperparathyroidism. Consumption of late stage chronic kidney disease therapeutics help to relieve the symptoms of CKD, delay late stage chronic kidney disease development, and thus enable patients to live longer lives without going through dialysis or transplantation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising prevalence of chronic kidney disease (CKD) worldwide, rising awareness among people regarding the benefits of late stage chronic kidney disease therapeutics, introduction of favorable reimbursement policies for CKD treatment, higher diagnostic rates, and development of new effective therapeutics are some of the major factors expected to boost the growth of late stage chronic kidney disease therapeutics market during the forecast period.
Increasing incidence of chronic kidney disease is perhaps the major factor behind the robust expansion of late stage chronic disease therapeutics market. According to a report published in the Lancet, global prevalence of chronic kidney diseases reached around 700 million in 2017 and the numbers are expected to further surge during the upcoming years.
Similarly, the introduction of new advanced late stage kidney disease therapeutics along with poor access to renal replacement therapy and dialysis in developing countries is expected to favor market growth during the assessment period.
Despite its optimistic stance, the late stage chronic kidney disease therapeutics market is facing various obstacles that are restraining its growth to some extent. Some of these growth restraining factors are the delay in the diagnosis of CKD and increase in the number of kidney transplants.
Similarly, various side effects associated with late stage chronic kidney disease therapeutics is also limiting market growth.
Principal Consultant
According to Future Market Insights, North America accounted for the largest share of the global late stage chronic kidney disease therapeutics market in 2021 and is projected to grow at the fastest CAGR over the forecast period. Growth in the market is attributable to the rising incidence of chronic kidney disease, availability of favorable reimbursement policies, and heavy presence of leading market players.
Demand for late stage chronic kidney disease therapeutics is particularly high across the United States due to surge in chronic kidney disease cases and easy availability of advanced therapeutics. According to the Centers for Disease Control and Prevention (CDC), around 37 million people in the United States are estimated to have chronic kidney disease.
The Asia Pacific late stage chronic kidney disease therapeutics market is anticipated to grow at a considerable pace during the forecast period between 2022 and 2032, owing to the rising health awareness, growing prevalence of chronic kidney disease, and increasing government initiatives and investments to reduce the burden of chronic kidney disease.
According to the National Kidney Foundation, number of cases of kidney failure is expected to surge rapidly in developing countries, such as China and India, where the number of elderly people is increasing. This will generate lucrative growth prospects within the Asia Pacific late stage chronic kidney disease therapeutics market during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key participants present in the global late stage chronic kidney disease therapeutics market includes Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire, Vifor and ZS Pharma among others.
These leading players are continuously investing in research and development to introduce more effective therapeutics. Besides this, they are partnering and collaborating with dialysis centers to increase their sales and gain a competitive edge in the market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 11.6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global late stage chronic kidney disease therapeutics market to expand at a stupendous CAGR of around 11.6% through 2032.
North America is forecast to remain the most lucrative market for late stage chronic kidney disease therapeutics during the assessment period.
Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, and Spectrum are some prominent late stage chronic kidney disease therapeutics manufacturers
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Calcimimetics
5.3.2. Vitamin D Sterols
5.3.3. Phosphate Binding Therapies
5.3.4. Potassium Binding Therapies
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032
6.3.1. Late-stage Chronic Kidney Disease - Induced Hyperparathyroidism
6.3.2. Late-stage Chronic Kidney Disease - Induced Hyperphosphatemia
6.3.3. Late-stage Chronic Kidney Disease - Induced Hyperkalemia
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Mail Order Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
Deep-dive segmentation will be available in the sample on request
8. Global Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Indication
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Indication
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Indication
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Indication
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Indication
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Indication
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. East Asia Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Indication
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia & Pacific Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Drug Class
13.2.3. By Indication
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. MEA Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Indication
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Late Stage Chronic Kidney Disease Therapeutics Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Drug Class
15.1.2.2. By Indication
15.1.2.3. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Drug Class
15.2.2.2. By Indication
15.2.2.3. By Distribution Channel
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Drug Class
15.3.2.2. By Indication
15.3.2.3. By Distribution Channel
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Drug Class
15.4.2.2. By Indication
15.4.2.3. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Drug Class
15.5.2.2. By Indication
15.5.2.3. By Distribution Channel
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Drug Class
15.6.2.2. By Indication
15.6.2.3. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Drug Class
15.7.2.2. By Indication
15.7.2.3. By Distribution Channel
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Drug Class
15.8.2.2. By Indication
15.8.2.3. By Distribution Channel
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Drug Class
15.9.2.2. By Indication
15.9.2.3. By Distribution Channel
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Drug Class
15.10.2.2. By Indication
15.10.2.3. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Drug Class
15.11.2.2. By Indication
15.11.2.3. By Distribution Channel
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Drug Class
15.12.2.2. By Indication
15.12.2.3. By Distribution Channel
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Drug Class
15.13.2.2. By Indication
15.13.2.3. By Distribution Channel
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Drug Class
15.14.2.2. By Indication
15.14.2.3. By Distribution Channel
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Drug Class
15.15.2.2. By Indication
15.15.2.3. By Distribution Channel
15.16. ASEAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Drug Class
15.16.2.2. By Indication
15.16.2.3. By Distribution Channel
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Drug Class
15.17.2.2. By Indication
15.17.2.3. By Distribution Channel
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Drug Class
15.18.2.2. By Indication
15.18.2.3. By Distribution Channel
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Drug Class
15.19.2.2. By Indication
15.19.2.3. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Drug Class
15.20.2.2. By Indication
15.20.2.3. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Amgen Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. OPKO Pharmaceuticals Medtronic Plc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Abbott Laboratories
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Sanofi-Aventis U.S.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Takeda Pharmaceutical
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Vifor Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Akebia Therapeutics
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. AstraZeneca
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Kyowa Hakko Kirin
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Galenica Group
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Late Stage Chronic Kidney Disease Therapeutics Market
